Treprostinil derivatives and compositions and uses thereof
The present disclosure provides treprostinil derivatives that can act as prodrugs of treprostinil. The treprostinil derivatives can be used to treat any conditions responsive to treatment with treprostinil, including pulmonary hypertension, such as pulmonary arterial hypertension.
1. A pharmaceutical composition comprising one or more pharmaceutically acceptable excipients or carriers and a compound selected from the group consisting of:
and pharmaceutically acceptable salts, solvates, hydrates, clathrates, polymorphs and stereoisomers thereof.
2. The composition of claim 1 , which is configured for transdermal delivery of the compound.
3. The composition of claim 2 , which is configured as a transdermal patch.
4. A method of treating a medical condition responsive to treatment with treprostinil, comprising administering to a subject in need of treatment a therapeutically effective amount of a compound selected from the group consisting of:
and pharmaceutically acceptable salts, solvates, hydrates, clathrates, polymorphs and stereoisomers thereof.
5. The method of claim 4 , wherein the medical condition is selected from the group consisting of pulmonary hypertension, pulmonary fibrosis, congestive heart failure, peripheral vascular disease, atherogenesis, peripheral ischemic lesions on the skin, critical limb ischemia, diabetic neuropathic foot ulcer, kidney malfunction and failure, tumors, cancers, and pain associated with each of the preceding conditions.
6. The method of claim 5 , wherein the medical condition is pulmonary hypertension.
7. The method of claim 6 , wherein the medical condition is pulmonary arterial hypertension.
8. The method of claim 7 , further comprising administering a vasoactive agent, a diuretic, an anticoagulant or a cardiac glycoside, or any combination thereof.
9. The method of claim 4 , wherein the compound is administered transdermally.
10. The method of claim 9 , wherein the compound is administered via a transdermal patch.
11. A compound selected from the group consisting of:
and pharmaceutically acceptable salts, solvates, hydrates, clathrates, polymorphs and stereoisomers thereof.